Last quarter (Q3 2023), Terns Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Terns Pharmaceuticals's net income was $-29.77M. See Terns Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	-	$ 1.00M	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	$ 1.00M	-	-	-
Operating Expense	$ 95.33M	$ 62.03M	$ 50.86M	$ 37.02M	$ 70.20M	$ 18.45M
Operating Income	$ -95.33M	$ -62.03M	$ -49.86M	$ -37.02M	$ -70.20M	$ -18.45M
Net Non Operating Interest Income Expense	-	-	-	$ 55.00K	$ 1.20M	$ 332.00K
Other Income Expense	$ -10.82M	$ -2.04M	$ -210.00K	$ -2.79M	$ 154.00K	$ 38.00K
Pretax Income	$ -84.50M	$ -59.99M	$ -49.65M	$ -39.76M	$ -68.84M	$ -18.09M
Tax Provision	$ 508.00K	$ 358.00K	$ 508.00K	$ 813.00K	$ -20.00K	$ -67.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -85.01M	$ -60.34M	$ -50.16M	$ -29.35M	$ -68.61M	$ -17.71M
Basic EPS	$ -2.21	$ -1.67	$ -2.21	$ -1.29	$ -2.86	$ -0.74
Diluted EPS	$ -1.11	$ -1.67	$ -2.21	$ -1.29	$ -2.86	$ -0.74
Basic Average Shares	$ 248.71M	$ 36.03M	$ 22.71M	$ 22.72M	$ 23.97M	$ 23.97M
Diluted Average Shares	$ 248.71M	$ 36.03M	$ 22.71M	$ 22.72M	$ 23.97M	$ 23.97M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 95.33M	$ 62.03M	$ 50.86M	$ 37.02M	$ 70.20M	$ 18.45M
Net Income From Continuing And Discontinued Operation	$ -85.01M	$ -60.34M	$ -50.16M	$ -40.05M	$ -68.61M	$ -17.71M
Normalized Income	$ -23.47M	$ -47.39M	-	$ -40.05M	$ -68.61M	$ -17.71M
Interest Expense	-	-	-	-	-	-
EBIT	$ -84.50M	$ -59.99M	$ -49.65M	$ -37.02M	$ -70.20M	$ -18.45M
EBITDA	$ -87.71M	$ -58.87M	$ -48.26M	$ -36.63M	$ -70.00M	$ -18.39M

Currency in USD

Terns Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing